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Abstract
Class switch recombination and somatic hypermutation occur in mature B-cells in response to antigen stimulation. These
processes are crucial for the generation of functional antibodies. During HIV-1 infection, loss of memory B-cells, together
with an altered differentiation of naı ¨ve B-cells result in production of low quality antibodies, which may be due to impaired
immunoglobulin affinity maturation. In the current study, we evaluated the effect of HIV-1 infection on class switch
recombination and somatic hypermutation by studying the expression of activation-induced cytidine deaminase (AID) in
peripheral B-cells from a cohort of chronically HIV-1 infected patients as compared to a group of healthy controls. In parallel,
we also characterized the phenotype of B-cells and their ability to produce immunoglobulins in vitro. Cells from HIV-1
infected patients showed higher baseline levels of AID expression and increased IgA production measured ex-vivo and upon
CD40 and TLR9 stimulation in vitro. Moreover, the percentage of CD27
2IgA
+ and CD27
2IgG
+ B-cells in blood was
significantly increased in HIV-1 infected patients as compared to controls. Interestingly, our results showed a significantly
increased number of somatic hypermutations in the VH genes in CD27
2 cells from patients. Taken together, these results
show that during HIV-1 infection, CD27
2 B-cells can also produce class switched and somatically hypermutated antibodies.
Our data add important information for the understanding of the mechanisms underlying the loss of specific antibody
production observed during HIV-1 infection.
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Introduction
The ability of B-cells to differentiate into antibody secreting
cells (ASC) that produce highly specific antibodies (Abs) is the
key for a successful immune response against pathogens [1].
Upon encountering an antigen (Ag), mature naı ¨ve B-cells
migrate to the secondary lymphoid organs where they organize
germinal centers (GC) and undergo immunoglobulin (Ig) affinity
maturation [2]. Two physiological processes are taking place at
this stage, class switch recombination (CSR) and somatic
hypermutation (SHM). CSR allows a previously rearranged Ig
heavy chain variable (V) domain to be expressed in association
with a different constant region, leading to production of
different isotypes (IgG, IgA or IgE), with improved effector
functions [3,4,5]. In SHM the V domains of immunoglobulin
may increase their affinity by accumulations of mutations. These
processes are fundamental for the quality of the immune
response and for development of an efficient serologic memory
to prevent re-infections [1].
During HIV-1 infection the B-cell compartment displays several
alterations [6]; naı ¨ve B-cells, which normally lack CD27
expression [7], have an altered expression of several differentiation
markers and hypergammaglobulinemia is frequently observed
[8,9]. However, despite high levels of serum IgG, the patients are
unable to mount specific immune responses towards HIV-1 [10]
or other pathogens [8]. This is partly due to a loss of memory B-
cells (defined as CD19
+CD27
+) [7] which undergo spontaneous
apoptosis [11] leading to loss of serologic memory [12]. Although
the currently available Highly-Active Anti Retroviral Therapy
(HAART) is able to normalize the proportion of different B-cell
subpopulations in chronically HIV-1 infected patients [13],
serologic memory cannot be restored [12]. This suggests that
primary HIV-1 infection might be a crucial event for the
elimination of Ag-specific subpopulations of memory B-cells [14].
CSR and SHM are both dependent on the expression of the
enzyme activation-induced cytidine deaminase (AID) [3,15].
Moreover, CSR is a highly regulated process, controlled by
soluble cytokines and by T-cell membrane interaction between
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humans, switching to IgG is stimulated by the cytokines IL-10 and
IL-4 whereas IgA expression is also promoted by TGF-b [17,18].
The evidence that isotype switching is a highly CD40-dependent
event is demonstrated in the hyper-IgM syndrome, where almost
no secondary isotypes are produced as a result of a mutated
CD40L [19].
Different effects of purified HIV-1 proteins on CSR have
previously been reported [20,21] where nef was shown to be taken
up by B-cells and subsequently suppressed CSR by inducing IkBa
and SOCS proteins, thereby blocking CD40 ligand and cytokine
signalling via NF-kB and STAT proteins. These data suggest that
HIV-1 may evade T-cell dependent IgA and IgG responses
through interaction between nef and B-cells [21]. However,
purified env was shown to upregulate AID expression, thus
inducing CSR in a subset of B-cells expressing mannose C-type
lectin receptors (MCLRs) [20]. This subset of B-cells required B-
cell-activating factor (BAFF) for up-regulation of the MCLRs in
order for Ab secretion to occur. These results indicate that env
triggers IgA and IgG responses by activating MCLR expressing B-
cells through a CD40-independent pathway, thus impairing
protective T-cell-dependent Ab responses [20]. Taken together,
these data [20,21] suggest that different mechanisms underlie the
impaired T-cell dependent- and independent- Ab responses during
HIV-1 infection.
In the current study, we evaluated the effect of HIV-1 infection
on CSR by studying a cohort of chronically HIV-1 infected
patients, with low levels of HIV-1 viral load and treated with
HAART, as compared with a group of healthy controls. In
particular, we characterized the phenotype of B-cells, measured
the levels of AID expression and Ig production upon stimulation of
peripheral blood mononuclear cells (PBMCs) in vitro. Moreover,
we measured the percentage of CD27
2 cells amongst all IgA
+ and
IgG
+ B-cells in blood and analyzed the VH region of Ig
transcripts.
Methods
Study design and population
Blood from 38 HIV-1 infected individuals and 29 healthy
controls were collected. In the HIV-1 cohort, the median CD4
+ T-
cell count was 752 cells/ml (range 70–1164 cells/ml) and the viral
load ranged from ,20 to 681 copies/ml blood. The viral load was
determined using the NASBA system (Organon Teknika, Boxtel,
the Netherlands). In order to minimize the impact of viral
replication on the studied parameters, all the recruited patients
were under HAART with a median time of 83 months of
treatment (13–188 months). Due to the limited amount of blood
available from a single individual, all patients could not be
included in all analyses (23 controls and 22 patients for studies of
AID expression and measurement of IgA and IgG levels, 20
controls and 20 patients for IgA intracellular staining, 17 controls
and 25 patients for IgG intracellular staining and 4 controls and 4
patients for sequencing of the VH regions from different B-cell
subpopulations). Written informed consent was obtained from all
subjects before enrolment and the ethical committees of the
Karolinska University Hospital and Karolinska Institutet approved
the study.
Cell preparation and flow cytometry
PBMC from the study subjects were purified from 20–30 mL of
EDTA-treated whole blood by centrifugation over a Ficoll-
Hypaque density gradient. Flow cytometric cell-phenotyping on
fresh isolated PBMCs were performed using the following
fluorochrome conjugated anti-human Abs: anti-IgA-fluorescein
isothiocyanate (FITC) (Dako, Stockholm, Sweden), anti-IgG-FITC
(Pharmingen, San Diego, CA), anti-CD27-phycoerythrin (PE)
(Pharmingen, San Diego, CA) and anti CD19- Cy-Chrome (Cy5)
(Pharmingen, San Diego, CA) in addition to isotype control Abs
(Pharmingen, San Diego, CA) to set the background staining
intensity. IgA and IgG were detected with intracellular staining by
the IntraStain kit (Dako, Stockholm, Sweden). The analysis was
performed with a FACScalibur instrument (Becton Dickinson,
Mountain View, CA, USA) using the CellQuest software (Becton
Dickinson, Mountain View, CA, USA). Forward/side scatter dot
plot was used to gate the live lymphocyte population. Anti-IgD-
FITC, anti CD27-PE and anti CD19-Cy5 (Pharmingen, San
Diego, CA) were used for cell sorting on a FACSAria instrument
(Becton Dickinson, Mountain View, CA, USA) using the
FACSDiva software (Becton Dickinson, Mountain View, CA,
USA).
Activation of B-cells in PBMC cultures
PBMCs were washed in phosphate-buffered saline (PBS) and
resuspended in complete RPMI medium (Sigma, Stockholm,
Sweden). Cells were cultured in 48 well plates at a concentration of
1610
6 cells/well with 1 ml of medium or medium supplemented
with 1 mg/ml of anti-CD40 mAb (Diaclone, Besancon, France),
100 ng/ml IL-4 (ImmunoTools GmbH, Germany) and 50 ng/ml
IL-10 (Peprotech, London, UK) or 10 mg/mL cytosine guanine
dinucleotide (CpG) oligodeoxynucleotide (ODN) 2006 (CpG type
B) (Microsynth, Balgach, Switzerland) at 37uCi n5 %C O 2. The
cultures were run in duplicates and after 48 hrs of culture, cells
were collected for total RNA extraction while cells in the
remaining wells were maintained in culture until supernatants
were collected at day 9 and stored at 220uC until tested. The total
number of B-cells was analyzed by FACS and differences between
the samples were not statistically significant.
Enzyme-Linked Immunosorbent Assay (ELISA)
Total IgA and IgG Abs were measured in 9-day culture
supernatants. Briefly, 96 well plates (Corning Inc., NY, USA) were
coated with 50 ml/well of goat anti-human IgA and G (H+L)
(Dako, Stockholm, Sweden) diluted 1:1000 in Sodium Carbonate
buffer 0.1 M overnight at +4uC. Plates were then washed four
times with PBS containing 0.1% Tween-20 (Sigma, Stockholm,
Sweden) and samples with serial dilutions (experiments were
performed in duplicates) in PBS-Tween were added to the plates
and incubated overnight. Plates were then washed four times with
PBS-Tween and Horseradish peroxidase (HRP)-conjugated rabbit
anti-human IgA or IgG (Dako, Stockholm, Sweden) was added
and the plates were subsequently incubated for 1 hour at room
temperature. After a final wash, the plates were incubated with
HRP substrate buffer until absorbances were read with a
Labsystems Multiscan Bichromatic plate reader at a wavelength
of 405 nm and analysed with a Deltasoft II programme
(BioMetallics, Princeton, NJ, USA). The fold difference of IgA
and IgG production between non-stimulated and stimulated cells
was calculated by dividing the levels of Igs after stimulation with
the spontaneous Igs production of non-stimulated cells left in
culture medium for 9 days.
RNA isolation and first-strand cDNA synthesis
Total RNA was purified using the RNeasy minikit (QIAGEN,
Valencia, CA, USA) from purified PBMCs (approximately 1610
6
cells) or sorted B-cell subpopulations (2–8610
5 cells). Total RNA
was reverse transcribed into first-strand cDNA using a using a
cDNA synthesis kit (GE Healthcare, Stockholm, Sweden).
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Quantitative real time polymerase chain reaction (RT-PCR)
was performed on an ABI PRISM 7900HT sequence detection
system (Applied Biosystems, Stockholm, Sweden). The primers
used for amplification of the AID transcripts were the following:
forward 59-CACCACTATGGACAGCCTCTTG-39 and reverse
59-ACTGTCACGCCTC-TTCACTACG-39, and for endogenous
control b-actin: forward 59-CTGGCACCACACCTTCTACAA-
39 and reverse 59-CAGCCTGGATAGCAACGTACA-39. Ampli-
fication was performed for 40 cycles, each cycle consisting of 94uC
for 50 sec, 62uC for 1 min, and 72uC for 1 min. The relative AID
expression level was calculated as described previously [22].
PCR amplification and analysis of the VH-Cc clones
The primers used for amplification of VH3-Cc and VH3-23-Cc
transcripts were VH3-consensus (59-aatctagaGGTGCAGCTG-
GTGGAGTC-39) or VH3-23 (59-tctagaGGCTGAGCTGGC-
TTTTTCTTGTGG-39) and CcB( 5 9-cagtcgacAAGACC-
GATGGGCCCTTGGTGG-39). The oligonucleotides contained
a restriction site (underlined, a Xba I site in the in the VH3-
consensus or VH3-23 primer and a Sal I site in the CcB primer)
for directional cloning of the PCR products. Amplification was
performed in 35 cycles, each cycle consisting of 94uC5 0s e c ,
62uC1m i na n d7 2 uC 1 min. High fidelity DNA polymerases
Vent (New England BioLabs, Hertfordshire, England, GB) or
Pfu (Fermentas Life Sciences, Burlington, Canada) were used for
the amplification. The PCR products were purified and cloned
into the Bluescript II KS (+) vector (Stratagene, La Jolla, CA,
USA) and transformed into JM 109 competent cells. The
resulting clones were screened by PCR amplification (VH3-
consensus or VH3-23 and CcB) and positive clones were
sequenced by an automated fluorescent sequencer in the
MWG Co. (Macrogen, Seoul, South Korea). Sequence analysis
was performed using the IMGT/V-QUEST (http://imgt.cines.
fr) to align the VH-CcB sequences to their closest germline VH,
D, and JH segment counterparts.
Statistical analyses
Regression analyses were performed using Sigma Stat for
Windows software (SPSS Inc, Chicago, USA). Differences
between patients and controls were analysed by parametric (t
test) or non-parametric (Mann-Whitney-U-test) tests. Results are
presented as mean values6standard deviation or percentages.
Results
AID expression is different in controls and HIV-1 infected
patients ex-vivo but it reaches similar levels following
anti-CD40 and TLR9 stimulation in-vitro
The baseline level of AID mRNA expression in non-
stimulated cells was higher in chronically HIV-1 infected
patients (12.3610.0) as compared to healthy controls (2.261.1)
(P=0.02) (Fig. 1A, left panel). Following 48 hours of anti-CD40
stimulation (anti-CD40 mAb, IL4 and IL10) AID expression
reached similar levels in both patients (84.4674.4) and controls
(89.5641.5) (Fig. 1A, middle panel). Following 48 hours of
TLR9 stimulation, AID expression also reached similar levels in
both patients (18.2614.1) and controls (15.968.5) (Fig. 1A, right
panel). In order to test whether AID expression correlated to the
proportion of CD27
+ memory (CD27
+)B - c e l l s ,w ec o m p a r e dt h e
AID expression at baseline and the CD27
+ B-cells percentage by
regression analyses. Interestingly, a statistically significant
correlation (R=0.5, P=0.04) was observed in the control group
(Fig. 1B) but not in patients (Fig. 1C). The expression of AID was
subsequently investigated in sorted CD27
2 and CD27
+ B-cells
from a subgroup of patients (n=3) and controls (n=3).
Although, due to the small number of samples tested, the
difference did not reach statistical significance, a higher level of
AID expression in patient CD27
2 B-cells was observed
(40.3633.1 vs 12.662.7 in controls), whereas a lower level of
AID expression was observed in the CD27
+ compartment for
patients (9.768.0 vs 64.0637.0 in controls).
Blood cells from HIV-1 infected patients produce higher
levels of IgA in vitro
To assess Ig production from B-cells, PBMCs isolated from the
blood of HIV-1 infected patients were cultured in vitro. High levels
of IgA were spontaneously produced in the culture medium by
patient B-cells (2496193 ng/mL) as compared to healthy controls
(72671 ng/mL) (P=0.008) (Fig. 2A, left panel). The same trend
was found after 9 days of stimulation with anti-CD40 Ab
(9656468 vs 378677 ng/mL) (P,0.001) (Fig. 2A, middle panel)
or TLR9 stimulation with CpG (8146189 vs 3756191 ng/mL)
(P,0.001) (Fig. 2A, right panel). No differences between patients
and controls were however observed for spontaneous IgG
production (16046296 vs 15906128 ng/mL) (Fig. 2B, left panel)
while upon anti-CD40 stimulation, IgG production reached
slightly higher levels in patients (1300767005 ng/mL) as com-
pared to controls (922367590 ng/mL) (P=0.05) (Fig. 2B, middle
panel). The TLR9 stimulation is less potent as compared to anti-
CD40 stimulation but induced similar IgG levels in patients
(28256594 ng/mL) and controls (333761468 ng/mL) (Fig. 2B,
right panel). Interestingly, stimulation through TLR9 induced a
low fold increase of IgG in both the patient and control groups (1.8
vs 2.1 fold) as compared with anti-CD40 stimulation (8.1 vs 5.8
fold).
Expanded populations of CD27
2 IgA
+ and CD27
2 IgG
+ B-
cells are found in the blood of HIV-1 infected patients
The high baseline levels of AID together with the finding that
AID expression did not correlate with the CD27
+ B-cell counts in
HIV-1 infected patients might suggest the involvement of CD27
2
B-cells in Ig production. In order to investigate whether CD27
2 B-
cells in HIV-1 infected patients produce class switched Abs, we
measured the percentage of CD27
2 B-cells amongst IgA
+ or IgG
+
B-cells in the blood of patients and controls. Intriguingly, the
results showed a significant increase of the percentage of CD27
2
B-cells among all intracellular IgA (27 vs 15%, P=0.04) and IgG
(47 vs 19%, P,0.001) positive cells in patients as compared to
healthy controls (Fig. 3A and B).
The VH genes in CD27
2 B-cells from HIV-1 infected
individuals are highly mutated
In order to evaluate the ability of different B-cell sub-
populations to produce somatically hypermutated Abs, we sorted
cells from 4 additional patients and 4 healthy individuals by flow
cytometry. To increase the purity of the sorting, CD19
+CD27
2
and CD19
+CD27
+ B-cells were also sorted according to the
surface expression of IgD. The VH region of the mRNA
transcripts for CD19
+CD27
2IgD
+ and CD19
+CD27
+IgD
2 B-
cells were PCR amplified using either a VH3 consensus primer or
a VH3-23 specific primer, together with a Cc specific primer. In
total, 53 and 49 VH-Cc sequences were generated from B-cells of
patients and controls respectively (Table 1). Among those, 45 and
37 represented distinct B-cell clones, with unique complementar-
ity-determining region 3 (CDR3) sequences and these clones were
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Table 1 and Figure 3C, while the VH genes amplified from
CD19
+CD27
2IgD
+ cells in the control group had a low number of
mutations, as expected (average 3 mutations per gene; mutated in
1.2% bp sequenced), the VH genes from patient
CD19
+CD27
2IgD
+ cells had a significantly higher number of
mutations (20 mutations per gene, P,0.001; mutated in 6.3% bp
sequenced). Conversely, the VH genes from the
CD19
+CD27
+IgD
2 cells from patients, which would be expected
to have a higher number of mutations, had a significantly reduced
number of mutations as compared to the controls (15 vs 25
mutations per gene respectively, P,0.001; 4.8% vs. 8.3% bp
sequenced). The ratio of replacement vs silent mutations (R/S) was
similar in the patient and control groups for both CD27
+ and
CD27
2 cells, suggesting that there was no major difference in the
Ab selection process (Table 1).
Discussion
During primary HIV-1 infection, a high degree of viral
replication and CD4
+ T-cell depletion occur. In parallel, a large
proportion of the CD27
+ B-cells die by apoptosis while CD27
2 B-
cells are characterized by a modified phenotype [14]. Successful
HAART normalizes B-cell subpopulation percentages in blood
[13]. During HAART, however, many commensal and opportu-
nistic micro-organisms which are normally kept under control by
the immune system, are more active within the respiratory tract
[23], the gut [24] and the brain [25] resulting in the presence of
microbial products in the body [26]. In this scenario, B-cells may
be more susceptible to activation and differentiation into ASC by
polyclonal stimuli [27]. During chronic HIV-1 infection, Ag
specific Ab titres are decreased while the total amount of
circulating IgG is elevated (hypergammaglobulinemia) [10].
Figure 2. IgA and IgG production in vitro in HIV-1 infected patients and healthy controls. (A) The levels of IgA before (left panel) and after
in vitro stimulation (anti-CD40 mAb, IL4 and IL10 or CpG, middle and right panels) are higher in patients (black bars) as compared with controls (white
bars). (B) The levels of IgG before (left panel) and after in vitro stimulation (middle and right panels) are similar in patients (black bars) as compared
with controls (white bars).
doi:10.1371/journal.pone.0005427.g002
Figure 1. AID expression in HIV-1 infected patients and healthy controls. (A) The ex-vivo levels of AID mRNA expression (left panel) are
higher in patients (black bars) as compared with controls (white bars) but they reach similar levels upon in vitro stimulation (middle and right panels).
The baseline levels of AID mRNA expression correlate with the percentage of CD27
+ B cells in healthy controls (B) while there is no correlation for HIV-
1 infected patients (C). The anti-CD40 stimulation was performed with an anti-CD40 mAb, IL4 and IL10 while TLR9 stimulation with CpG.
doi:10.1371/journal.pone.0005427.g001
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patients with chronic HIV-1 infection as compared to healthy
controls. Moreover, the levels of AID at baseline did not correlate
to the proportion of the CD27
+ B-cells in the patients suggesting
that CD27
2 B-cells may contribute to an increased baseline AID
expression. AID up-regulation is normally associated with GC B-
cells [28]. However, high levels of extra-follicular AID expression
have previously been reported in non-stimulated PBMCs from
HIV-1 infected patients and found to be associated with
development of AIDS associated non-Hodgkin B-cell lymphoma
(AIDS-NHL) [29]. In addition, it has been shown in a mouse
model that over expression of AID in B-cells induced production
of pathogenic multireactive Abs [30]. In HIV-1 infection, several
studies have reported the presence of multi-reactive low affinity
Abs in serum and it is possible that high baseline AID expression
leads to the production of auto Abs.
Bacterial CpG DNA motifs have previously been shown to
activate B-cells by TLR9 ligation which induces IgG CSR [31].
Recently, a viral double stranded RNA was shown to induce
production of class switched Abs through the engagement of
TLR3 in the upper respiratory tract mucosa [32]. We found that
in B-cells from patients with chronic HIV-1 infection, AID
expression was induced in vitro upon CD40-dependent and TLR9
stimulation but less efficiently than in controls where the fold
increase was much higher. Interestingly, it has been shown that B-
cells from aged mice respond poorly to anti-CD40 activation and
have a lower AID expression compared to B-cells from young mice
[33]. Our finding may therefore support the hypothesis that B-cells
are prematurely exhausted during HIV-1 infection [34]. On the
other hand, despite the higher baseline AID expression observed
in B-cells from patients, the levels of AID reached similar levels in
stimulated cells from both patients and controls. The lower fold
increase observed in patients could also be interpreted as a result
of an inefficient stimulation in the patient samples as they are
already partly stimulated. In our experiments, the consequences of
virus particles, present during primary infection and non-treated
chronic infection, were minimized since all the patients received
HAART. Thus, the ability of B-cells during chronic infection to
express AID, the prerequisite for CSR, in response to different
stimuli could be evaluated in vitro. However, the presence of a small
fraction of T-cells carrying replication competent HIV-1 virus in
our cultures [35] cannot be excluded.
We also investigated Ig production ex vivo and upon anti-CD40
and TLR9 stimulation. High IgA levels were found in cultures
from non-stimulated HIV-1 patient cells as well as upon anti-
CD40 and TLR9 stimulation where patient cells secreted more
IgA as compared to controls. In this cohort of treated patients, we
could not detect any significant increase in spontaneous IgG
secretion. This is in accordance with a previous study where the
majority of aviremic HAART treated patients had normal IgG
levels [36]. Moreover, we observed that anti-CD40 stimulation
only significantly increased IgG but not IgA production in both
patients and controls. This might be due to the combined effect of
the anti-CD40 Ab and of the cytokines IL-10 and IL-4 which are
known to induce switching towards IgG, whereas IgA expression is
also promoted by TGF-b [17,18]. On the other hand, TLR9-
driven activation of B-cells induced a high IgA production in
patient cells as compared to controls. This might be a common
and physiological phenomenon in the gut where the majority of
Abs produced against commensal bacteria are of the IgA class
[37,38]. Thus, the increased ability of B-cells from HIV-1 infected
patients to respond to stimulation and produce IgA, might reflect
an increased response to microbial products [26] in HIV-1
infected individuals. Interestingly, the levels of IgA and IgG
produced spontaneously and upon stimulation in culture were
higher in cultures with cells from patients with CD4 ,350 cells/ml
of blood compared to patients with higher CD4 T-cell counts,
although the results did not reach statistical significance (data not
shown).
Our results on AID expression and the lack of correlation to the
memory B-cell population in HIV-1 infected individuals may
suggest that CD27
2 B-cells participate in the production of class
Table 1. Mutations in VH3-Cc transcripts from sorted CD272IgD+ and CD27+IgD2 B cells from HIV-1 infected patients and
healthy controls.
All clones Distinct Unmutated
Total mutations in V
region
Total bp
sequenced
Frequency of
mutations (% bp)
*R/S
**CDRs-
**FRs
HIV-1
CD272IgD+ 20 13 0 240 3809 6.3 6.1–2.1
CD27+IgD2 33 32 0 443 9178 4.8 4.2–2.1
Controls
CD272IgD+ 20 12 9 40 3406 1.2 6.6–1.0
CD27+IgD2 29 25 0 592 7105 8.3 4.6–2.1
The SHM pattern analysis was performed in the distinct clones.
*Replacements/silent mutations.
**Complementarity-determining region.
***Framework region.
doi:10.1371/journal.pone.0005427.t001
Figure 3. HIV-1 infected patients present with expanded populations of blood CD27
2 IgA
+ and CD27
2 IgG
+ B-cells and show
inverse patterns of SHM. The percentage of CD27
2IgA
+ (A) and CD27
2IgG
+ (B) among total IgA/G expressing B-cells is significantly expanded in
HIV-1 infected patients (right panel) as compared with healthy controls (left panel). (C) The number of somatic hypermutations in the VH region of
mRNA transcripts of CD27
2 B cells (left panel) is increased in HIV-1 infected patients (black bars), as compared with healthy controls (white bars),
while an opposite trend is shown for CD27
+ B cells (right panel), where the number of somatic hypermutations in the VH region of mRNA transcripts
is decreased in HIV-1 infected patients (black bars) as compared with healthy controls (white bars). The number below the bars indicates the number
of clones analysed.
doi:10.1371/journal.pone.0005427.g003
CSR and SHM in HIV-1 Infection
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supported by our additional findings that both CD27
2IgA
+ and
CD27
2IgG
+ B-cells are expanded in the blood of HIV-1 infected
patients. However, it is also possible that IgA
+ or IgG
+ memory B-
cells from HIV-1 patients down-regulate CD27. In a previous
report, metalloprotease inhibitors were shown to block the release
of CD27 and enhance the immune stimulatory activity of chronic
lymphocytic leukemia cells [39]. Ongoing HAART regimens
consist of a cocktail of drugs often including a protease inhibitor;
therefore it is possible that different HAART schedules may result
in cleavage of the CD27 molecule from the cell surface [40]. The
levels of soluble CD27 in HAART treated HIV-1 infected patients
have previously been suggested as a marker of immune activation
[41]. CD27
2 B-cells expressing intracellular IgG have previously
also been found to be expanded in patients suffering with systemic
lupus erythematosus (SLE) [42]. In healthy individuals, CD27
2 B-
cells have also been described and defined as a new B-cell memory
subtype expressing VH genes with low frequency of SHM [43]. To
our knowledge, this is the first report showing the presence of IgA
+
B-cells lacking the expression of CD27 in the blood of healthy
individuals. However, while comparing the percentage of
CD27
2IgA
+ and CD27
2IgG
+ B-cells to the AID expression and
Ig production ex-vivo and upon in vitro stimulation, it was not
possible to find a significant correlation between these parameters
(data not shown). This could be due to the low percentages of these
B-cell populations compared to others in peripheral blood.
In order to verify whether CD27
2 B-cells represent a
population of memory B-cells, we studied the SHM pattern in
the Ig VH region of Cc transcripts of CD27
2IgD
+ B-cells. Our
data show that CD27
2 B-cells sorted from HIV-1 infected patients
contain Cc transcripts in which the VH region carry a high
number of somatic hypermutations compared to the controls.
Therefore, the CD27
2 B-cells in HIV-1 infected individuals may
represent a part of the memory B-cell pool. Based on these data,
we suggest that the CD19
+CD27
2IgD
+ population of both
controls and HIV-1 patients may contain B-cells that are in the
process of switching to IgG/IgA. In this respect, it is possible that
the co-expression of IgD and IgG/IgA by CD27
2 B cells during
HIV-1 infection is increased.
In addition, from the analysis on the Ig VH region from the
sorted CD27
+IgD
2 B-cells, we could observe a decrease in the
number of somatic hypermutations in HIV-1 patients compared to
healthy controls. SHM occurs during B-cell development, in the
GC reaction, and, upon Ag-encounter a new mutation may be
inserted when B-cells replicate and divide. Our data suggests that
CD27
+ B-cells during HIV-1 are either depleted after a few cell
divisions, or prevented from entering the GC. We have recently
shown that during chronic HIV-1 infection, CD27
+ and CD27
2
B-cells show an altered migration patterns due to alterations in
expression of the receptor-ligand pair CXCR5/CXCL13 [44].
The dysfunctional memory B-cell compartment in HIV-1 infected
patients may thus be due to both altered CD27
2 B-cells with a
memory phenotype and exhausted CD27
+ B-cells with impaired
regulation of CSR. Evidence for HIV-associated B-cell exhaustion
and dysfunctional memory B-cell compartment has recently been
reported for HIV-1 infected viremic individuals [34]. Most
importantly, clinical observations indicate that the loss of
serological memory persists during chronic infection and that
specific Ab titers cannot be recovered in patients who still present
with hypergammaglobulinemia upon HAART treatment [8,12].
We thus propose a model where CD27
2 B-cells are more prone
to respond to unspecific signals such as polyclonal bystander
activation and TLR triggering by microbial products during HIV-
1 infection. This would result in the expansion of CD27
2 IgA
+ and
IgG
+ B-cells [43] in blood. The levels of AID and the presence of a
high number of somatic hypermutations in the Ig VH region of
CD27
2 B-cell transcripts demonstrated that these B-cell subpop-
ulations have undergone Ig affinity maturation. In this scenario,
the lack of specific immune responses during HIV-1 infection
would be due both to the involvement of CD27
2 B-cells in CSR
and SHM, triggered by unspecific stimuli [31,45], and to CD27
+
B-cell exhaustion. This could be a consequence of persistent
pathogen reactivation and microbial translocation shown during
chronic HIV-1 infection [26]. A possible impairment in the TLR
pathways in HIV-1 infected individuals should also be considered
in the pathogenesis of the autoimmune phenomena occurring
during HIV-1 infection [46] since there is increasing evidence that
TLRs, reactive with autologous ligands, play a major role in these
events [47].
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